Palvella Therapeutics, Inc. Number of Reportable Segments
Palvella Therapeutics, Inc. (PVLA) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-04
- Palvella Therapeutics, Inc. number of reportable segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- Palvella Therapeutics, Inc. number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segment.
- Palvella Therapeutics, Inc. number of reportable segments for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
- Palvella Therapeutics, Inc. number of reportable segments for fiscal 2024 was 1.00 Segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-31 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |